Cargando…

Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

Detalles Bibliográficos
Autores principales:	Goldstein, Lori J., Perez, Raymond P., Yardley, Denise, Han, Linda K., Reuben, James M., Gao, Hui, McCanna, Susan, Butler, Beth, Ruffini, Pier Adelchi, Liu, Yi, Rosato, Roberto R., Chang, Jenny C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238734/ https://www.ncbi.nlm.nih.gov/pubmed/32434589 http://dx.doi.org/10.1186/s13058-020-01294-7

Ejemplares similares

A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer
por: Goldstein, Lori J., et al.
Publicado: (2020)

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)
por: Goldstein, Lori J., et al.
Publicado: (2021)

The CXCL8-CXCR1/2 Axis as a Therapeutic Target in Breast Cancer Stem-Like Cells
por: Ruffini, Pier Adelchi
Publicado: (2019)

The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the Gata1 (low) Mice
por: Verachi, Paola, et al.
Publicado: (2022)

Blockade of CXCR1/2 chemokine receptors protects against brain damage in ischemic stroke in mice: Ischemia and Reparixin
por: da Cunha Sousa, Larissa Fonseca, et al.
Publicado: (2013)

CXCR1/2 pathways in paclitaxel-induced neuropathic pain
por: Laura, Brandolini, et al.
Publicado: (2017)

Multiple anti-tumor effects of Reparixin on thyroid cancer
por: Liotti, Federica, et al.
Publicado: (2017)

The protective effects of reparixin against endothelial ischemia-reperfusion injury
por: Thitiwuthikiat, Piyanuch, et al.
Publicado: (2022)

Ladarixin, an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2, in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial
por: Piemonti, Lorenzo, et al.
Publicado: (2022)

Risperidone-related bilateral cystoid macular edema: a case report
por: Kozlova, Anna, et al.
Publicado: (2019)

A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia
por: Landoni, Giovanni, et al.
Publicado: (2022)

The effect of reparixin on survival in patients at high risk for in-hospital mortality: a meta-analysis of randomized trials
por: Landoni, Giovanni, et al.
Publicado: (2022)

Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling
por: Brandolini, Laura, et al.
Publicado: (2015)

Window of Opportunity
Publicado: (1996)

In vitro ultraviolet–induced damage in human corneal, lens, and retinal pigment epithelial cells
por: Youn, Hyun-Yi, et al.
Publicado: (2011)

Letter to the Editor Regarding a Multicentric Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia
por: Ito, Shun, et al.
Publicado: (2022)

Response to “Letter to the Editor Regarding a Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia”
por: Mantelli, Flavio
Publicado: (2022)

Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia: A Phase 3, Randomized, Double-Blind Placebo-Controlled Study
por: Piemonti, Lorenzo, et al.
Publicado: (2023)

Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in mice
por: Ruffini, Pier Adelchi, et al.
Publicado: (2014)

In vitro assessment of the biocompatibility of chemically treated silicone materials with human lens epithelial cells
por: Kao, Elizabeth C. Y., et al.
Publicado: (2022)

Involvement of CXCR4 Chemokine Receptor in Metastastic HER2-Positive Esophageal Cancer
por: Gros, Stephanie J., et al.
Publicado: (2012)

Windows of opportunity for the peopling of the Americas
por: Lesnek, Alia J.
Publicado: (2023)

Correction: Involvement of CXCR4 Chemokine Receptor in Metastastic HER2-Positive Esophageal Cancer
por: Gros, Stephanie J., et al.
Publicado: (2013)

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients
por: Lefort, S, et al.
Publicado: (2017)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
por: Adamo, Barbara, et al.
Publicado: (2019)

Windows of opportunity for daily physical activity
por: Du, Marvin
Publicado: (2020)

A Window of Opportunity for Newborn Screening
por: Bailey Jr, Donald B.
Publicado: (2022)

Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study
por: D’Angelo, Alberto, et al.
Publicado: (2022)

In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway
por: Pils, D, et al.
Publicado: (2007)

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
por: Yardley, D A, et al.
Publicado: (2014)

Gestational diabetes mellitus: A window of opportunity
por: Kalra, Sanjay, et al.
Publicado: (2011)

Response: How to Use a Window of Opportunity
por: Chisolm, Margaret S., et al.
Publicado: (2011)

A Window of Opportunity for Cognitive Training in Adolescence
por: Knoll, Lisa J., et al.
Publicado: (2016)

A window of opportunity for cooperativity in the T Cell Receptor
por: Martin-Blanco, N., et al.
Publicado: (2018)

Window of opportunity trials in head and neck cancer
por: Farlow, Janice L., et al.
Publicado: (2019)

Opening windows of opportunity for smoking cessation treatment
por: Castellano, Maria Vera Cruz de Oliveira
Publicado: (2018)

Diabetic retinopathy: An often missed window of opportunity
por: Chawla, Rajeev
Publicado: (2023)

Interleukin-8 as a therapeutic target for chronic low back pain: Upregulation in human cerebrospinal fluid and pre-clinical validation with chronic reparixin in the SPARC-null mouse model
por: Krock, Emerson, et al.
Publicado: (2019)

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer
por: Pascual, Tomás, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3pg0edq0vkdouqrranue47g7l6